SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhou, P. Articles by Craig, R. W. Search for Related Content PubMed PubMed Citation Articles by Zhou, P. Articles by Craig, R. W. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 June 2001, Vol. 97, No. 12, pp. 3902-3909 NEOPLASIA MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes Ping Zhou, Norman B. Levy, Haiyi Xie, Liping Qian, Chi-Yu Gregory Lee, Randy D. Gascoyne, and Ruth W. Craig From the Departments of Pharmacology and Toxicology, Pathology, and Community and Family Medicine, Dartmouth Medical School, Hanover, NH; and Andrology Laboratory, Department of Obstetrics and Gynecology, University of British Columbia; and Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver, BC, Canada. Viability-promoting genes such as BCL2 play an important role in human cancer but do not directly cause aggressive tumors. BCL2 transgenic mice develop lymphoma at low frequency, hindering studies of tumorigenesis and its inhibition in the presence of such gene products. MCL1 is a member of the BCL2 family that is highly regulated endogenously and that promotes cell viability and immortalization when introduced exogenously. Mice expressing an MCL1 transgene in hematolymphoid tissues have now been monitored for an extended period and were found to develop lymphoma with long latency and at high probability (more than 85% over 2 years). In most cases, the disease was widely disseminated and of clonal B-cell origin. A variety of histologic subtypes were seen, prominently follicular lymphoma and diffuse large-cell lymphoma. MCL1 thus sets the stage for the development of lymphoma as does BCL2, disease occurring with high probability and recapitulating a spectrum of subtypes as seen in human patients. These findings with the transgene underscore the importance of the normal, highly regulated pattern of MCL1 expression, in addition to providing a model for studying tumorigenesis and its inhibition in the presence of a viability promoting BCL2 family member. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. H. Cho, S. Goenka, T. Henttinen, P. Gudapati, A. Reinikainen, C. M. Eischen, R. Lahesmaa, and M. Boothby PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells Blood, March 12, 2009; 113(11): 2416 - 2425. [Abstract] [Full Text] [PDF] H. Su, J.-R. Yang, T. Xu, J. Huang, L. Xu, Y. Yuan, and S.-M. Zhuang MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity Cancer Res., February 1, 2009; 69(3): 1135 - 1142. [Abstract] [Full Text] [PDF] A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis Cancer Res., November 1, 2008; 68(21): 8705 - 8714. [Abstract] [Full Text] [PDF] Q. Ding, L. Huo, J.-Y. Yang, W. Xia, Y. Wei, Y. Liao, C.-J. Chang, Y. Yang, C.-C. Lai, D.-F. Lee, et al. Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer Cancer Res., August 1, 2008; 68(15): 6109 - 6117. [Abstract] [Full Text] [PDF] A. Ruiz-Vela, M. Aggarwal, P. de la Cueva, C. Treda, B. Herreros, D. Martin-Perez, O. Dominguez, and M. A. Piris Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways Blood, February 1, 2008; 111(3): 1665 - 1676. [Abstract] [Full Text] [PDF] F. A. Masri, W. Xu, S. A. A. Comhair, K. Asosingh, M. Koo, A. Vasanji, J. Drazba, B. Anand-Apte, and S. C. Erzurum Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L548 - L554. [Abstract] [Full Text] [PDF] A. De Biasio, J. A. Vrana, P. Zhou, L. Qian, C. K. Bieszczad, K. E. Braley, A. M. Domina, S. J. Weintraub, J. M. Neveu, W. S. Lane, et al. N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells J. Biol. Chem., August 17, 2007; 282(33): 23919 - 23936. [Abstract] [Full Text] [PDF] Q. Ding, X. He, W. Xia, J.-M. Hsu, C.-T. Chen, L.-Y. Li, D.-F. Lee, J.-Y. Yang, X. Xie, J.-C. Liu, et al. Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3{beta} Activity and Associates with Poor Prognosis in Human Breast Cancer Cancer Res., May 15, 2007; 67(10): 4564 - 4571. [Abstract] [Full Text] [PDF] P. Klener, M. Szynal, Y. Cleuter, M. Merimi, H. Duvillier, F. Lallemand, C. Bagnis, P. Griebel, C. Sotiriou, A. Burny, et al. Insights into Gene Expression Changes Impacting B-Cell Transformation: Cross-Species Microarray Analysis of Bovine Leukemia Virus Tax-Responsive Genes in Ovine B Cells J. Virol., February 15, 2006; 80(4): 1922 - 1938. [Abstract] [Full Text] [PDF] Y. K. Lee, C. R. Isham, S. H. Kaufman, and K. C. Bible Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy Mol. Cancer Ther., January 1, 2006; 5(1): 138 - 148. [Abstract] [Full Text] [PDF] C. Gelinas and E. White BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis Genes & Dev., June 1, 2005; 19(11): 1263 - 1268. [Full Text] [PDF] R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma J. Clin. Pathol., May 1, 2005; 58(5): 520 - 524. [Abstract] [Full Text] [PDF] S. S. Park, J. S. Kim, L. Tessarollo, J. D. Owens, L. Peng, S. S. Han, S. Tae Chung, T. A. Torrey, W. C. Cheung, R. D. Polakiewicz, et al. Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice Cancer Res., February 15, 2005; 65(4): 1306 - 1315. [Abstract] [Full Text] [PDF] R. Gerl and D. L. Vaux Apoptosis in the development and treatment of cancer Carcinogenesis, February 1, 2005; 26(2): 263 - 270. [Abstract] [Full Text] [PDF] S. Kitada and J. C. Reed MCL-1 Promoter Insertions Dial-Up Aggressiveness of Chronic Leukemia J Natl Cancer Inst, May 5, 2004; 96(9): 642 - 643. [Full Text] [PDF] A. Egle, A. W. Harris, P. Bouillet, and S. Cory Bim is a suppressor of Myc-induced mouse B cell leukemia PNAS, April 20, 2004; 101(16): 6164 - 6169. [Abstract] [Full Text] [PDF] N. W. C. J. van de Donk, D. Schotte, M. M. J. Kamphuis, A. M. W. van Marion, B. van Kessel, A. C. Bloem, and H. M. Lokhorst Protein Geranylgeranylation Is Critical for the Regulation of Survival and Proliferation of Lymphoma Tumor Cells Clin. Cancer Res., November 15, 2003; 9(15): 5735 - 5748. [Abstract] [Full Text] [PDF] A. M. Ranger, J. Zha, H. Harada, S. R. Datta, N. N. Danial, A. P. Gilmore, J. L. Kutok, M. M. Le Beau, M. E. Greenberg, and S. J. Korsmeyer Bad-deficient mice develop diffuse large B cell lymphoma PNAS, August 5, 2003; 100(16): 9324 - 9329. [Abstract] [Full Text] [PDF] A. V. Terskikh, T. Miyamoto, C. Chang, L. Diatchenko, and I. L. Weissman Gene expression analysis of purified hematopoietic stem cells and committed progenitors Blood, July 1, 2003; 102(1): 94 - 101. [Abstract] [Full Text] [PDF] J.-H. Yoon, N. W. Werneburg, H. Higuchi, A. E. Canbay, S. H. Kaufmann, C. Akgul, S. W. Edwards, and G. J. Gores Bile Acids Inhibit Mcl-1 Protein Turnover via an Epidermal Growth Factor Receptor/Raf-1-dependent Mechanism Cancer Res., November 15, 2002; 62(22): 6500 - 6505. [Abstract] [Full Text] [PDF] S. Inoshita, K. Takeda, T. Hatai, Y. Terada, M. Sano, J. Hata, A. Umezawa, and H. Ichijo Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress J. Biol. Chem., November 8, 2002; 277(46): 43730 - 43734. [Abstract] [Full Text] [PDF] G. Z. Rassidakis, R. Lai, T. J. McDonnell, F. Cabanillas, A. H. Sarris, and L. J. Medeiros Overexpression of Mcl-1 in Anaplastic Large Cell Lymphoma Cell Lines and Tumors Am. J. Pathol., June 1, 2002; 160(6): 2309 - 2310. [Full Text] [PDF] P. I. Chuang, S. Morefield, C.-Y. Liu, S. Chen, J. M. Harlan, and D. M. Willerford Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1 Blood, May 1, 2002; 99(9): 3350 - 3359. [Abstract] [Full Text] [PDF] B. Zhang, I. Gojo, and R. G. Fenton Myeloid cell factor-1 is a critical survival factor for multiple myeloma Blood, March 15, 2002; 99(6): 1885 - 1893. [Abstract] [Full Text] [PDF] J. A. Vrana, C. K. Bieszczad, E. S. Cleaveland, Y. Ma, J. P. Park, T. K. Mohandas, and R. W. Craig An MCL1-overexpressing Burkitt Lymphoma Subline Exhibits Enhanced Survival on Exposure to Serum Deprivation, Topoisomerase Inhibitors, or Staurosporine but Remains Sensitive to 1-{beta}-D-Arabinofuranosylcytosine Cancer Res., February 1, 2002; 62(3): 892 - 900. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020